ZWJ Investment Counsel Inc. raised its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 26.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,176 shares of the biopharmaceutical company’s stock after purchasing an additional 3,209 shares during the period. ZWJ Investment Counsel Inc.’s holdings in Bristol-Myers Squibb were worth $789,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in BMY. Trust Co. of Virginia VA increased its holdings in shares of Bristol-Myers Squibb by 105.7% in the 4th quarter. Trust Co. of Virginia VA now owns 50,048 shares of the biopharmaceutical company’s stock valued at $2,601,000 after acquiring an additional 25,712 shares during the last quarter. Highwater Wealth Management LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $170,000. Yorktown Management & Research Co Inc increased its holdings in shares of Bristol-Myers Squibb by 400.0% in the 3rd quarter. Yorktown Management & Research Co Inc now owns 20,000 shares of the biopharmaceutical company’s stock valued at $1,242,000 after acquiring an additional 16,000 shares during the last quarter. Hollencrest Capital Management increased its holdings in shares of Bristol-Myers Squibb by 176.1% in the 4th quarter. Hollencrest Capital Management now owns 9,604 shares of the biopharmaceutical company’s stock valued at $499,000 after acquiring an additional 6,126 shares during the last quarter. Finally, Northern Capital Management LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $3,907,000. 73.35% of the stock is currently owned by institutional investors.
Shares of BMY opened at $49.96 on Friday. The firm has a market cap of $80.88 billion, a P/E ratio of 12.55, a P/E/G ratio of 2.22 and a beta of 0.81. The company has a quick ratio of 1.50, a current ratio of 1.61 and a debt-to-equity ratio of 0.40. Bristol-Myers Squibb Co has a 12 month low of $44.30 and a 12 month high of $67.44.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a dividend of $0.41 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a yield of 3.28%. Bristol-Myers Squibb’s payout ratio is currently 41.21%.
BMY has been the subject of a number of research analyst reports. BMO Capital Markets reiterated a “buy” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a report on Thursday, January 3rd. Societe Generale upgraded Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a report on Tuesday, January 15th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a report on Tuesday, March 5th. Edward Jones downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Friday, January 4th. Finally, Morgan Stanley set a $54.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Thursday, December 20th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $59.40.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: Derivative
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.